CDK4/6 inhibitors for breast cancer on SilverScript Choice (S5601-052)
Ibrance, Kisqali and Verzenio, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), New Mexico
- Premium
- $104.00/month
- Deductible
- $615.00
3 of 3 CDK4/6 inhibitors are covered on this plan. All 3 require prior authorization.
- from $3,568.04Tier 5
- 25%Tier 5
- 25%Tier 5
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.